Revlimid revenue growth
In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Revlimid’s fiscal 2018 net product sales of around $9.7 billion. In the first nine months of 2018, Revlimid saw worldwide sales of $7.14 billion, which is a YoY rise of 18.95%. Out of these revenues, $4.74 billion were earned from the US market, which is a YoY rise of 19.90%. International markets contributed $2.40 billion worth of revenues, which is a YoY rise of 17.11%.
In the third quarter, Revlimid saw worldwide sales of $2.45 billion, which is YoY growth of 18%. Out of these revenues, $1.67 billion came from the US market, which is a YoY rise of 22%.
According to the company’s third-quarter earnings conference call, the company has witnessed a rise in the duration of therapy, especially for Revlimid-based triplet combination regimens in the US market. The company has also benefitted from the rapid uptake of Revlimid from newly diagnosed multiple myeloma (or NDMM) patients who are not eligible for stem cell transplant as well as from post-transplant multiple myeloma patients in the maintenance setting.
In the third quarter, Revlimid reported sales worth $782 million from international markets, which is a YoY rise of 8.61%. This performance was mainly driven by 18% YoY growth in sales volumes. However, according to the company’s third-quarter earnings conference call, YoY revenue growth rates were affected by the Russian tender offer for Revlimid in Q3 2017. The Russian tender coupled with clinical trial revenues also resulted in higher Revlimid by around $100 million from international markets in the second quarter as compared to the third quarter.
In the next article, we’ll discuss label expansion initiatives for Revlimid in greater detail.